Innocan Pharma's Promising Synthetic Cannabidiol Development

Innocan Pharma's Narrative Review at PAINWEEK Conference

Herzliya and Calgary, June 2025 - Innocan Pharma Corporation (CSE: INNPF), a leader in the pharmaceutical and biotechnology sectors, is thrilled to announce that its recent narrative review, titled "Considering Long-Acting Synthetic Cannabidiol for Chronic Pain: A Narrative Review," has been accepted for presentation at PAINWEEK 2025. This prominent conference, focused on pain management, is set to take place in September.

Significance of the PAINWEEK Conference

PAINWEEK is a renowned event within the medical community, uniting experts, clinicians, and educators to explore the latest advancements in pain management. The conference serves as a significant platform for presenting innovative research and sharing best practices aimed at improving patient outcomes. Innocan's narrative review was selected following a rigorous peer-review process, reflecting its high caliber and relevance.

Innovative Developments in Cannabidiol

At the core of Innocan's advancements is LPT-CBD, a groundbreaking injectable liposomal product designed for the sustained release of synthetic cannabidiol (CBD). Remarkably, animal studies have shown that LPT-CBD maintains stable plasma CBD levels for up to four weeks, providing extended pain relief with outstanding tolerability. This development presents a viable alternative to traditional opioid medications, addressing the ongoing public health crisis regarding opioid dependency.

Showcasing LPT-CBD at PAINWEEK

LPT-CBD will be prominently featured at the PAINWEEK conference, where it will be presented to healthcare professionals and potential pharmaceutical partners. This exposure positions Innocan at the forefront of non-opioid chronic pain management solutions.

Innocan's Leadership Statement

"We are honored to be recognized among the influential voices presenting at PAINWEEK this year," stated Iris Bincovich, Chief Executive Officer of Innocan. "This acknowledgement is a testament to our dedication to advancing pain care based on solid evidence and contributing significant research in the field."

About Innocan Pharma

Innocan Pharma is a front-runner in the pharmaceuticals and wellness industries. In pharmaceuticals, the company has innovated a CBD-loaded liposome delivery system that ensures precise dosing along with prolonged and controlled release of synthetic CBD for effective non-opioid pain relief. The wellness division features a diverse range of high-performance self-care and beauty products designed to enhance a healthy lifestyle. Under this segment, Innocan operates through its 60% owned subsidiary, BI Sky Global Ltd., which specializes in targeted online sales.

Contact Information

For further inquiries regarding Innocan Pharma Corporation, please contact:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377

Frequently Asked Questions

What is LPT-CBD?

LPT-CBD is Innocan Pharma's innovative injectable product designed for the extended release of synthetic cannabidiol to provide prolonged pain relief.

When will Innocan present at PAINWEEK?

Innocan's narrative review will be presented at PAINWEEK 2025 in September.

How does Innocan's product differ from traditional pain medications?

The product offers an alternative to opioids, focusing on a non-opioid approach to chronic pain management, aiming to reduce dependency issues.

What audience will Innocan target at PAINWEEK?

The company aims to reach thousands of healthcare professionals and potential pharmaceutical partners interested in innovative pain management solutions.

Is the review available for public access?

Yes, the narrative review has been published and is open for peer-reviewed access, showcasing important insights into the application of synthetic CBD.

About The Author

Dedicated Author and financial expert Logan Wright here, 29 years old. After earning an economics degree, I spent a number of years working in different financial industries. My great passion is enabling everyone, from any background or experience level, to understand and be literate in financial matters.

My books and writings are centered on simplifying difficult financial ideas into doable, understandable guidance. Whether it's retirement planning, investing, or budgeting, I want to arm readers with the information they need to make wise financial choices and realize their financial objectives.

Apart from writing, I also frequently post to financial blogs and organize webinars and workshops targeted at enlightening participants about personal finance. Always, my strategy is to offer concise, doable advice that can truly improve people's lives.

Away from work, I like to read, travel, and sample new foods. My goal is to infuse everything I do with the balance that I think is essential to both financial and personal well-being. By my profession, I want to encourage and enable people to confidently and clearly take charge of their financial futures.

Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.